Peregrine Pharma (PPHM) Posts Mixed Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Noble Financial Positive on Peregrine Pharma (PPHN) Following Q4 Report; Says Contract Manufacturing to Drive Revs
July 15, 2016 12:01 PM EDTNoble Financial affirms Peregrine Pharma (Nasdaq: PPHM) witha Buy rating and $1.50 price target after the company announced Q4 and FY16 results on Thursday night.
Analyst Kumaraguru Raja, PhD, noted the following today:
Focus on value creation. Peregrine continues to focus on value creation driven by Avid contract manufacturing... MorePeregrine Pharma (PPHM) Enters Exclusive Novel Exosome Technology Licensing Agreement
July 14, 2016 8:08 AM EDTPeregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that the company has entered into an exclusive licensing agreement with University of Texas (UT) Southwestern Medical Center for a novel exosome technology that has potential application as a simple blood test to detect or monitor cancer. The company intends to develop a novel cancer test utilizing internal expertise and then pursue revenue-generating partnering opportunities at an early stage of development.
Tumor exosomes represent small pieces of tumor cells that are released into the blood as tumors grow. Tumor derived exosomes have... More
